A Mixed Mirror-image DNA/RNA Aptamer Inhibits Glucagon and Acutely Improves Glucose Tolerance in Models of Type 1 and Type 2 Diabetes

• Published in: The Journal of biological chemistry Vol. 288; no. 29; pp. 21136 - 21147
• Main Authors: Vater, Axel, Sell, Simone, Kaczmarek, Przemyslaw, Maasch, Christian, Buchner, Klaus, Pruszynska-Oszmalek, Ewa, Kolodziejski, Pawel, Purschke, Werner G., Nowak, Krzysztof W., Strowski, Mathias Z., Klussmann, Sven
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 19.07.2013; American Society for Biochemistry and Molecular Biology
• Subjects: Animals; Aptamers; Aptamers, Nucleotide - blood; Aptamers, Nucleotide - pharmacokinetics; Aptamers, Nucleotide - pharmacology; Aptamers, Nucleotide - therapeutic use; Blood Glucose - metabolism; Body Weight - drug effects; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP - biosynthesis; Diabetes; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Disease Models, Animal; DNA; Drug Design; Drug Discovery; Fasting - blood; Glucagon - antagonists & inhibitors; Glucagon - metabolism; Glucagon Inhibitor; Glucose Tolerance Test; Humans; Kinetics; Male; Metabolism; Mice; Mice, Inbred BALB C; Mirror-image Aptamer; RNA - metabolism; Spiegelmer; Type 1 Diabetes; Type 2 Diabetes; Mirror-image Aptamer; Type 1 Diabetes; Spiegelmer; DNA; Type 2 Diabetes; Aptamers; Drug Design; Diabetes; Glucagon Inhibitor; Drug Discovery
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M112.444414

Excessive secretion of glucagon, a functional insulin antagonist, significantly contributes to hyperglycemia in type 1 and type 2 diabetes. Accordingly, immunoneutralization of glucagon or genetic deletion of the glucagon receptor improved glucose homeostasis in animal models of diabetes. Despite this strong evidence, agents that selectively interfere with endogenous glucagon have not been implemented in clinical practice yet. We report the discovery of mirror-image DNA-aptamers (Spiegelmer®) that bind and inhibit glucagon. The affinity of the best binding DNA oligonucleotide was remarkably increased (>25-fold) by the introduction of oxygen atoms at selected 2′-positions through deoxyribo- to ribonucleotide exchanges resulting in a mixed DNA/RNA-Spiegelmer (NOX-G15) that binds glucagon with a Kd of 3 nm. NOX-G15 shows no cross-reactivity with related peptides such as glucagon-like peptide-1, glucagon-like peptide-2, gastric-inhibitory peptide, and prepro-vasoactive intestinal peptide. In vitro, NOX-G15 inhibits glucagon-stimulated cAMP production in CHO cells overexpressing the human glucagon receptor with an IC50 of 3.4 nm. A single injection of NOX-G15 ameliorated glucose excursions in intraperitoneal glucose tolerance tests in mice with streptozotocin-induced (type 1) diabetes and in a non-genetic mouse model of type 2 diabetes. In conclusion, the data suggest NOX-G15 as a therapeutic candidate with the potential to acutely attenuate hyperglycemia in type 1 and type 2 diabetes. Background: An increased glucagon/insulin ratio is known to contribute to hyperglycemia in diabetes. Results: NOX-G15, a mirror-image mixed DNA/RNA glucagon-neutralizing aptamer, was identified. It improved glucose tolerance in models of type 1 and 2 diabetes. Conclusion: NOX-G15 may be useful for treatment of type 1 and 2 diabetes. Significance: The new therapeutic candidate may help to reduce insulin need in diabetes.